PRME Prime Medicine, Inc.

Nasdaq primemedicine.com


$ 3.72 $ 0.45 (13.35 %)    

Monday, 17-Nov-2025 15:47:04 EST
QQQ $ 602.34 $ -5.20 (-0.85 %)
DIA $ 466.18 $ -5.48 (-1.16 %)
SPY $ 664.83 $ -6.26 (-0.93 %)
TLT $ 89.11 $ 0.22 (0.25 %)
GLD $ 370.86 $ -4.31 (-1.15 %)
$ 3.82
$ 3.40
$ 3.71 x 2,544
$ 3.72 x 400
$ 3.34 - $ 3.73
$ 1.11 - $ 6.94
8,382,425
na
nm
$ 2.20
nm
TBD
na
na (nm)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-07-2025 09-30-2025 10-Q
2 08-07-2025 06-30-2025 10-Q
3 05-08-2025 03-31-2025 10-Q
4 02-28-2025 01-01-1970 10-K
5 11-12-2024 09-30-2024 10-Q
6 08-08-2024 06-30-2024 10-Q
7 05-10-2024 03-31-2024 10-Q
8 03-01-2024 12-31-2023 10-K
9 11-03-2023 09-30-2023 10-Q
10 08-07-2023 06-30-2023 10-Q
11 05-11-2023 03-31-2023 10-Q
12 03-09-2023 12-31-2022 10-K
13 11-14-2022 09-30-2022 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 citigroup-maintains-neutral-on-prime-medicine-lowers-price-target-to-425

Citigroup analyst Samantha Semenkow maintains Prime Medicine (NASDAQ:PRME) with a Neutral and lowers the price target from $...

 chardan-capital-maintains-buy-on-prime-medicine-lowers-price-target-to-9

Chardan Capital analyst Geulah Livshits maintains Prime Medicine (NASDAQ:PRME) with a Buy and lowers the price target from $...

 my-top-biotech-stock-picks-and-portfolio-strategy-for-the-next-3-10-years

Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds of...

 chardan-capital-maintains-buy-on-prime-medicine-lowers-price-target-to-10

Chardan Capital analyst Geulah Livshits maintains Prime Medicine (NASDAQ:PRME) with a Buy and lowers the price target from $...

 prime-medicine-q2-eps-041-misses-039-estimate-sales-1115m-beat-750000k-estimate

Prime Medicine (NASDAQ:PRME) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0....

 prime-medicine-announces-proposed-public-offering-of-common-stock-no-size-or-amount-disclosed

Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time cura...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION